Disease-Modifying Drug Possibly Linked to Placental Insufficiency: Severe placental complications in a pregnant woman with multiple sclerosis.
Disease-modifying drugs (DMDs) such as interferon (IFN)-β and glatiramer acetate are often prescribed to slow disability progression in patients with multiple sclerosis (MS). However, adverse pregnancy outcomes have been reported with these medications. We report the rare occurrence of severe placental complications in a 30-year-old pregnant woman with MS who continued to take IFN-β during her first trimester. She presented at the Tawam Hospital, Al Ain, United Arab Emirates, in 2013 with early-onset fetal growth restriction. At 30 gestational weeks, she developed severe pre-eclampsia. The baby was delivered via emergency Caesarean section and was discharged at the age of two months. Continuation of IFN-β during pregnancy may have contributed to the development of placental insufficiency in this patient. Increased education regarding the risks of DMDs for pregnant patients with MS is very important to ensure successful pregnancy outcomes.
Department of Pharmacy, Sheikh Zayed Hospital, Abu Dhabi, United Arab Emirates;
Sultan M
SM
Salahudheen
Department of Obstetrics & Gynaecology, Tawam Hospital, Al Ain, United Arab Emirates.
Muzibunnisa A
MA
Begam
Case Report; Fetal Growth Retardation; Interferon Beta; Multiple Sclerosis; Placental Insufficiency; Pre-Eclampsia; United Arab Emirates